Chemo-Free hope: new combo aims to outsmart CLL
NCT ID NCT04010968
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of two targeted drugs, venetoclax and ibrutinib, against standard chemotherapy (FCR) in 120 fit patients with intermediate-risk chronic lymphocytic leukemia (CLL). The goal was to see if the drug combo could achieve deep remission with a fixed treatment duration, guided by minimal residual disease (MRD) testing. Participants received ibrutinib alone for 3 months, then added venetoclax, with treatment stopping if MRD levels were very low at month 9.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax and ibrutinib
- What this could lead to
- If successful, this could offer a chemotherapy-free option for intermediate-risk CLL patients, potentially with a fixed treatment duration and better long-term outcomes.
- What could go wrong
- This is a phase 2 trial with only 120 participants, so results are preliminary. The targeted drugs may cause side effects like heart issues or infections, and the approach may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIT PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bordeaux Pessac
Pessac, 33604, France
-
CH Annecy Genevois - Hématologie A3
Annecy, 74374, France
-
CH BLOIS
Blois, 41000, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHR ORLEANS - Hématologie
Orléans, 44100, France
-
CHU Caen - IHBN - Hématologie Clinique
Caen, 14033, France
-
CHU Estaing - Hématologie Clinique Adulte
Clermont-Ferrand, 63000, France
-
CHU Grenoble - Hématologie
Grenoble, 388043, France
-
CHU Hôtel Dieu - Hématologie Clinique
Nantes, 44093, France
-
CHU Nancy Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CHU Pontchaillou - Hématologie Clinique BMT-HC
Rennes, 35033, France
-
Centre Henri Becquerel - Service Hématologie Clinique
Rouen, 76038, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Regional Metz Thionville
Metz, 57085, France
-
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, 91100, France
-
Centre Hospitalier du Mans
Le Mans, 72000, France
-
Centre Léon Bérard - Hématologie
Lyon, 69373, France
-
Ch Cote Basque
Bayonne, 64109, France
-
Chu Creteil
Créteil, 94000, France
-
Chu Reims
Reims, 51092, France
-
GRENOBLE GHM - Institut Daniel Hollard
Grenoble, 38028, France
-
Hôpital André Mignot
Versailles, 78157, France
-
Hôpital Avicenne - Centre de Recherche Clinique
Bobigny, 93009, France
-
Hôpital Bretonneau - Hématologie et Thérapie Cellulaire
Tours, 37044, France
-
Hôpital Hautepierre - Hématologie
Strasbourg, 67098, France
-
Hôpital Pitié Salpétrière - Hématologie
Paris, 75651, France
-
Hôpital Privé Sévigné
Cesson-Sévigné, 35510, France
-
Hôpital Saint Eloi
Montpellier, 34295, France
-
Hôpital Saint Vincent de Paul
Lille, 59000, France
-
Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire
Poitiers, 86021, France
-
IUCT ONCOPOLE - Hématologie
Toulouse, 31059, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Paoli Calmette
Marseille, 130009, France
-
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42271, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.